Table 5. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of esophageal adenocarcinoma (EA) for BMI and waist-hip ratio (WHR) in the SBES cohort.

	EA/total	Unadjusted HR(95% CI)	Adjusted for age† and gender HR(95% CI)	Adjusted for age†, gender, cigarette smoking‡ and NSAID¶ use HR(95% CI)
BMI
BMI continuous	45/397	0.99 (0.93–1.07)	1.02 (0.95–1.10)	1.01 (0.94–1.10)
BMI categories
≤25	6/54	REF	REF	REF
>25-≤30	22/188	0.91 (0.37–2.24)	1.00 (0.40–2.49)	0.88 (0.35–2.19)
>30-≤35	13/120	0.84 (0.32–2.22)	0.99 (0.37–2.63)	0.81 (0.31–2.18)
>35	4/35	0.86 (0.24–3.05)	1.33 (0.36–4.89)	1.21 (0.32–4.48)
p-value trend *		0.85	0.61	0.73
WHR
WHR male & female
Q1	8/99	REF	REF	REF
Q2	12/99	1.67 (0.68–4.09)	1.58 (0.64–3.88)	1.38 (0.56–3.40)
Q3	12/97	1.46 (0.60–3.58)	1.40 (0.57–3.44)	1.24 (0.50–3.05)
Q4	13/100	1.88 (0.78–4.55)	1.61 (0.66–3.92)	1.48 (0.60–3.61)
p-value trend *		0.01	0.12	0.16
Q2–Q4	37/294	1.66 (0.77–3.56)	1.53 (0.71–3.29)	1.36 (0.63–2.94)
WHR male
Q1	7/82	REF	REF	REF
Q2	11/80	1.84 (0.71–4.75)	1.67 (0.65–4.34)	1.44 (0.55–3.76)
Q3	11/78	1.62 (0.63–4.19)	1.50 (0.58–3.88)	1.32 (0.51–3.44)
Q4	12/82	1.98 (0.78–5.04)	1.72 (0.67–4.40)	1.53 (0.59–3.96)
p-value trend *		0.04	0.08	0.12
Q2–Q4	34/238	1.81 (0.80–4.08)	1.63 (0.72–3.69)	1.42 (0.62–3.26)
WHR female
Q1	1/17	REF	REF	REF
Q2	1/19	0.87 (0.05–13.94)	1.03 (0.06–16.77)	3.01 (0.09–99.07)
Q3	1/19	0.71 (0.04–11.39)	0.77 (0.05–12.45)	0.82 (0.05–13.62)
Q4	1/18	1.21 (0.07–19.69)	0.91 (0.05–15.19)	0.95 (0.05–18.92)
p-value trend *		0.97	0.86	0.75
Q2–Q4	3/56	0.89 (0.09 –8.54)	0.89 (0.09–8.59)	1.04 (0.10–10.96)

^†– Age modeled as a continuous variable,

^‡– Cigarette smoking modeled as a categorical variable (Current, Former, Never),

^¶– NSAID use modeled as a categorical variable (Current, Former, Never).

Q1: Quartile 1, Q2: Quartile 2, Q3: Quartile 3, Q4: Quartile 4.

^*Test for trend was based on the likelihood-ratio test associated with addition of the variable under consideration in its continuous form.